BioVentures is introducing its DMG Diversity Navigator™ system for determining genetic variants in genes coding for the major CYP450's of drug metabolism.
The DMG Diversity Navigator™ can be used to discover metabolic variants, metabolic risks, explain drug metabolism effects and to develop genotype/phenotype relationships. In addition, the DMG Diversity Navigator™ system can be utilized to better understand and possibly predict drug-drug interactions or other adverse events.
DMG Diversity Navigator™ systems are available for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, and POR.
Each system provides optimized primers and reagents that produce amplicons and sequence data specific for each exon and its flanking intronic segments. Advantages of the system include elimination of pre-research primer design, high specificity through single exon amplification and sequencing, room temperature reaction conditions, and compatibility with multiple assay formats.
Kits include buffers, amplification and forward and reverse sequencing primers for 200 samples, as well as, control DNA, protocols, BioTracker™ 6X Dye and a sample of BioMarker® EXT DNA molecular weight marker. The detailed protocol guides users through the system, starting with PCR and ending with data analysis. Users will have access to reference sequences and SNP information provided on the BioVentures' Web site.
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